Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vebreltinib in MET Exon 14 Mutated NSCLC
NCT05989542Phase 3Recruiting
- Sponsor
- Beijing Pearl Biotechnology Co., Ltd.
- Start
- Oct 2023
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of vebreltinib in non-small cell lung cancer (NSCLC), sponsored by Beijing Pearl Biotechnology Co., Ltd. Primary endpoint: Objective Response Rate at 2 years. Started Oct 2023; status: recruiting.
02
Drugs
vebreltinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05989542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05989542.